- Home
- NDSN vs EXEL Comparison
NDSN vs EXEL Comparison
Compare NDSN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDSN
- EXEL
- Stock Information
- Founded
- NDSN 1935
- EXEL 1994
- Country
- NDSN United States
- EXEL United States
- Employees
- NDSN N/A
- EXEL N/A
- Industry
- NDSN Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NDSN Industrials
- EXEL Health Care
- Exchange
- NDSN Nasdaq
- EXEL Nasdaq
- Market Cap
- NDSN 10.1B
- EXEL 10.4B
- IPO Year
- NDSN N/A
- EXEL 2000
- Fundamental
- Price
- NDSN $227.17
- EXEL $38.63
- Analyst Decision
- NDSN Strong Buy
- EXEL Buy
- Analyst Count
- NDSN 6
- EXEL 21
- Target Price
- NDSN $262.83
- EXEL $43.65
- AVG Volume (30 Days)
- NDSN 399.3K
- EXEL 3.8M
- Earning Date
- NDSN 08-20-2025
- EXEL 07-28-2025
- Dividend Yield
- NDSN 1.42%
- EXEL N/A
- EPS Growth
- NDSN N/A
- EXEL 81.76
- EPS
- NDSN 7.95
- EXEL 2.08
- Revenue
- NDSN $2,784,349,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- NDSN $5.77
- EXEL $9.88
- Revenue Next Year
- NDSN $4.99
- EXEL $12.59
- P/E Ratio
- NDSN $28.57
- EXEL $18.60
- Revenue Growth
- NDSN 4.49
- EXEL 10.73
- 52 Week Low
- NDSN $165.03
- EXEL $25.12
- 52 Week High
- NDSN $266.86
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- NDSN 62.43
- EXEL 45.22
- Support Level
- NDSN $213.23
- EXEL $37.40
- Resistance Level
- NDSN $235.71
- EXEL $38.78
- Average True Range (ATR)
- NDSN 5.11
- EXEL 0.85
- MACD
- NDSN 1.02
- EXEL 0.25
- Stochastic Oscillator
- NDSN 67.24
- EXEL 91.13
About NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.